Granulysin and its clinical significance as a biomarker of immune response and NK cell related neoplasms

doi:10.5315/wjh.v3.i4.128

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (23201)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-1) series.

Item

Count

PDF

11417

WORD

368

HTML

6644

Figures (1-6)

389

Tables (1-1)

253

Sum=19071

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

826

Download

1262

Sum=2088

Publishing Process of This Article

Item

Count

Browse

1078

Download

964

Sum=2042

Nov 6, 2014 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hematology

ISSN

2218-6204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hematol. Nov 6, 2014; 3(4): 128-137
Published online Nov 6, 2014. doi: 10.5315/wjh.v3.i4.128

Full Size Figure Download Figure

Figure 3 Schematic model of how granulysin kills target cell. (Cited from ref.[48] revised by author). NK: Natural killer; AIF: Apoptosis-inducing factor; CTL: Cytotoxic T lymphocytes.

Citation: Nagasawa M, Ogawa K, Nagata K, Shimizu N. Granulysin and its clinical significance as a biomarker of immune response and NK cell related neoplasms. World J Hematol 2014; 3(4): 128-137
URL: https://www.wjgnet.com/2218-6204/full/v3/i4/128.htm
DOI: https://dx.doi.org/10.5315/wjh.v3.i4.128